NCT05938946 - Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 30, 2023

Primary Completion Date

September 2, 2024

Study Completion Date

September 2, 2024

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

L608 Inhalation Solution

subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo

DRUG

Placebo solution

subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo

Trial Locations (1)

SA 5000

CMAX Clinical Research Pty Ltd, Adelaide